The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LEAPS, 2005Development and Optimization of a Regulatable Gene Switch for Gene Therapies of Parkinson’s Disease
Gene therapy holds tremendous potential for the treatment of Parkinson's disease. By using a virus or other DNA delivery system to permanently insert a new gene into critical regions of a Parkinson...
-
Community Fast Track, 2005Specific Inhibition of Nucleation of Alpha-synuclein Aggregation as a Therapeutic Strategy
There is considerable evidence that aggregates of the human brain protein alpha-synuclein are a primary cause of the loss of neurons in Parkinson's disease. We have tried to find out what initiates...
-
Community Fast Track, 2005Use of NR2D-selective NMDA Receptor Modulators in the Treatment of PD
The frontline pharmacological treatment for Parkinson’s disease is associated with serious side effects, creating a need for new therapeutic strategies. Recent evidence suggests that selective...
-
Specification, Patterning, and Maintenance of Midbrain Dopam, 2005Engineering Midbrain Dopamine Neurons by Forced Expression of a Novel Dopamine Cell Determinant in Pre-Clinical Model Embryonic Stem Cells
Understanding how the different cells of the brain are generated during embryonic development is one of the fundamental questions in biology. Recent studies have elucidated several key mechanisms...
-
Molecular Mechanisms of Dyskinesia in Parkinson's Disease, 2005Mechanisms of Graft-Induced Dyskinesias in an Animal Model of Parkinson's Disease (Supplemental Funding)
Our ongoing project has four aims:
- To develop a model of graft-induced dyskinesia (GID) in the rat, which will provide a cost-effective tool for studying the mechanisms of this complication;
- To...
-
The Role of Inflammation in Parkinson's Disease, 2005Development of a Dominant-Negative TNF Lentiviral Approach
Because TNF inhibitors are not believed to cross the blood-brain barrier, an orally administered TNF-based therapy is not currently possible. The Foundation has awarded supplemental funding to drive...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.